41 results about "Encephalitis" patented technology

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

The present invention provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified mRNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.

The invention discloses a human-mouse chimeric monoclonal antibody of GABABR1 protein and a product and application thereof, and belongs to the technical field of monoclonal antibodies, and the human-mouse chimeric monoclonal antibody comprises a mouse light chain variable region VL, a mouse heavy chain variable region VH, a human antibody light chain constant region and a human antibody heavy chain constant region. The mouse light chain variable region VL comprises three light chain complementary determining regions CDR1, CDR2 and CDR3, and the mouse heavy chain variable region VH comprises three heavy chain complementary determining regions CDR1, CDR2 and CDR3. The invention also provides a nucleic acid molecule, a vector and a host cell for coding the antibody, and application of the nucleic acid molecule, the vector and the host cell in preparation of a reagent / kit for detecting GABABR1 protein and a reagent / kit for resisting GABABR antibody-related encephalitis and / or prognosis.

Use of an NLRP3 inhibitor for treating encephalitis or meningitis. Specifically, provided is use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating encephalitis or meningitis, wherein each substituent is as defined in the description.

The application provides a severe encephalitis patient seizure automatic detection device based on brain network optimization, characterized by comprising an acquisition module, a preprocessing module and a detection module, the acquisition module acquires original electroencephalogram signals of the encephalitis patient to be detected; the preprocessing module inputs the detected electroencephalogram signals after preprocessing into a recognition model in the detection module to obtain a seizure detection result; the recognition model in the detection module integrates multiple brain networks and multiple features, more comprehensively reflects the relationship between each node in the brain network from multiple related dimensions; and the network layer and feature layer optimization based on the improved genetic algorithm realizes the optimal determination of multiple network weighting coefficients and multiple network weighting coefficients, takes the optimal network layer and feature layer as machine learning input, thereby greatly improving the accuracy of epilepsy recognition.

The invention belongs to the technical field of biology, and relates to a hybridoma cell strain and an antibody secreted by the hybridoma cell strain, in particular to an antigen epitope peptide for resisting Japanese encephalitis virus E protein, a monoclonal antibody, the hybridoma cell strain and application. The preservation number of the hybridoma cell strain is CCTCC (China Center For Type Culture Collection) NO: C2025313, the preservation date is 2025.10.16, and the preservation address is Wuhan University, Wuhan, China. The invention also discloses a monoclonal antibody 5B1 for resisting Japanese encephalitis virus, which is secreted by the hybridoma cell strain. According to the monoclonal antibody 5B1 for resisting JEV E provided by the invention, the amino acid sequence of an antigen epitope recognized by the monoclonal antibody 5B1 is 80-AHNEK-84, and the monoclonal antibody 5B1 is of a random curling structure; the monoclonal antibody 5B1 prepared by the invention has good specificity and reactivity, can specifically recognize JEV, and provides a research tool and material for researching the fusion process of JEV and host cells and developing a JEV diagnostic reagent.

A method of treating a subject suffering from an immune-mediated disease (e.g., IgA nephropathy, primary membranous nephropathy, an antibody-mediated rejection, lupus nephritis, systemic lupus erythematosus (SLE), Graves' Disease, Myasthenia Gravis, Anti-PLA2R positive Membranous Glomerulonephritis (aMN), Pemphigus, Sjögren's syndrome, and / or Anti-NMDA encephalitis) by administering to the subject a regimen of at least five doses of felzartamab and measuring a level of CD19+CD27hiCD38hi plasmablasts, a level of CD19+ B lymphocytes, or levels of CD19+CD27hiCD38hi plasmablasts and CD19+ B lymphocytes in a blood sample taken from the subject.

The application relates to an anti-NMDAR encephalitis clinical prognosis evaluation method based on artificial intelligence and belongs to the technical field of artificial intelligence and data processing. The method comprises the following steps: acquiring multi-modal neural image data of a patient; adopting a tensor decomposition fusion strategy to perform fusion preprocessing on the multi-modal neural image data, retaining cross-modal spatial correlation through low-rank constraint to obtain an output tensor after fusion; performing lesion-aware anisotropic diffusion filtering on the output tensor after fusion to obtain an output image after diffusion filtering; constructing an anti-NMDAR encephalitis clinical prognosis evaluation model, inputting the output image after diffusion filtering into the model for training, optimizing the training process by adopting an Adam adaptive optimizer, and finally obtaining a trained model; and inputting the output image after diffusion filtering to be evaluated into the trained model to obtain an evaluation classification result. The application can enhance the lesion recognition and classification capability of the model.

The present application relates to the field of biological medicine, and more particularly to a kind of anti-NMDAR encephalitis drug, curative effect analysis and mouse model establishment method.Mouse model has anti-GluN1 autoantibody, blood-brain barrier damage, IL-1β produced by endothelial cell;Whether mouse blood-brain barrier damage can be improved, the activity of endothelial cell IL-1β receptor is determined to determine the therapeutic effect by mouse model.Anakinra (Anakinra) is the drug for treating anti-NMDAR encephalitis.The present application can more accurately analyze and evaluate the cause and treatment effect of encephalitis by establishing humanized mouse model with anti-GluN1 (GluN1 is one subunit of NMDAR) antibody, blood-brain barrier damage and IL-1β produced by endothelial cell.

The invention relates to the technical field of biomedical detection, discloses a prediction model and system for predicting severity and prognosis of an anti-NMDAR encephalitis disease based on serum proteomics and a construction method of the prediction model and system, overcomes the defects and deficiencies in the prior art, and the constructed prediction model can be used for dynamically predicting severity and long-term prognosis of the anti-NMDAR encephalitis in the acute stage. Comprising the following steps: collecting a serum sample of an anti-NMDAR encephalitis patient; carrying out high-throughput proteomics detection on the serum sample by utilizing an Olink proximity extension analysis technology to obtain a standardized protein expression value; performing differential expression analysis on the standardized protein expression value of the anti-NMDAR encephalitis patient and the protein expression data of the healthy control group by using the multivariate linear model, and screening out differential expression proteins; the prediction model constructed by the random forest algorithm takes differential expression protein values as input and takes disease severity or follow-up prognosis as prediction result output; and evaluating the robustness of the prediction model through five-fold cross validation, and explaining the feature contribution by using a Shapley additive interpretation method.

The invention relates to methods of diagnosis or detection of Moissiacense virus, a novel orthobunyavirus causing human encephalitis, comprising determining the presence of at least one nucleic acid or protein of said virus or antibodies thereto, in a biological sample. The invention also relates to the various diagnostic agents derived from the viral nucleic acids or proteins, in articular nucleic acid primers and probes, antigens and antibodies, and their use for the diagnosis of Moissiacense virus infection and associated disease, in particular encephalitis. The invention further relates to antigens derived from the viral proteins as vaccine for the prevention of Moissiacense virus infection and associated disease, in particular encephalitis.

The application provides application of zinc pyrithione in preparation of a medicine for treating Japanese encephalitis virus infection. The application has the beneficial effect that the zinc pyrithione has significant inhibitory effect on NS2B-NS3 protease activity in the Japanese encephalitis virus, can be used as an inhibitor of the NS2B-NS3 protease in the Japanese encephalitis virus, and is expected to become a potential medicine for resisting Japanese encephalitis virus infection.

The application relates to MSBI (Multiple Sclerosis Brain Isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. These compounds are useful as early markers for the future development of cancer and diseases of the CNS (Multiple sclerosis MS, Prion-linked diseases, amyotrophic lateral sclerosis, transmissible spongiforme encephalitis, Parkinson's disease, Alzheimer disease) and should represent targets for treatment and prevention.

Described herein are single-domain antibodies that might serve as alternatives to conventional monoclonal antibodies for either the detection or treatment of Venezuelan equine encephalitis virus (VEEV).

The invention belongs to the technical field of biotechnology and genetic engineering, and relates to recombinant XAF1 and application of an inherent disorder region of the recombinant XAF1 in preparation of a medicine for preventing and treating herpes virus infection diseases. The XAF1 or the IDR fragment thereof provided by the invention can be combined with an STING RNA transcript and can promote the synthesis of endogenous STING. The invention also finds that XAF1 or an IDR fragment thereof can inhibit HSV-1 replication in vivo and in vitro, and alleviate nerve injury of herpes simplex encephalitis and pneumonia injury.

The application relates to application of CTRP4 in condition assessment and treatment of herpes simplex encephalitis, belongs to the technical field of biological medicine, and solves one of the problems that the condition assessment of HSE in the prior art is highly subjective, an imaging examination cannot reflect intracranial core lesions in real time and dynamically, is not related to a core biological mechanism of a disease, brain tissue samples are difficult to obtain, direct and effective indexes of intracranial disease states are scarce, and routine laboratory examinations are not specific for central nervous system pathologies and recovery of nerve functions. The application comprises application of CTRP4 in preparation of a herpes simplex encephalitis diagnostic reagent, and the diagnostic reagent is used for detecting the expression level of CTRP4 in a biological sample of a subject. The application of CTRP4 in preparation of the herpes simplex encephalitis diagnostic reagent can provide a highly specific, non-invasive and dynamic herpes simplex encephalitis condition assessment scheme, and solves the limitation problem of subjective diagnosis by doctors in traditional assessment.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

This invention provides a novel target PDE4B for the prevention and treatment of Cryptococcus neoformans brain infection. Specifically, it relates to the application of drugs targeting phosphodiesterase PDE4B in the preparation of drugs for the prevention and / or treatment of Cryptococcus neoformans meningoencephalitis. The drug targeting PDE4B is the PDE4B agonist MR-L2 (CAS: 2374703-19-0). The PDE4B agonist MR-L2 described in this invention can significantly reduce Cryptococcus neoformans brain infection, providing an effective prevention and treatment method for Cryptococcus neoformans meningoencephalitis.

The invention discloses an application of docosahexaenoic acid (DHA) in preparation of a medicine for treating anti-N-methyl-D-asparaginic acid receptor (NMDAR) encephalitis. The DHA is used for carrying out intervention treatment on NMDAR encephalitis mice, it is found that behavioristics, antibody titer, NMDAR endocytosis and hippocampal synaptic plasticity of the treated mice are recovered, and it is proved that DHA can be used for treating the NMDAR encephalitis antibody production mechanism. The invention provides a precise treatment medicine scheme aiming at pathogenesis for treating the anti-NMDAR encephalitis, can reduce the adverse reaction of more side effects in the existing first-line treatment, and has a good application prospect.

The invention discloses a construction method and application of an anti-NMDAR encephalitis disease animal model. The construction method comprises the following steps: mixing a GluN1 (359-378) peptide fragment and mycobacterium tuberculosis (Mtb) into an incomplete Freund adjuvant to obtain an emulsified mixture, performing subcutaneous injection to two sides of the back of an anesthetized mouse, and performing intraperitoneal injection of a pertussis toxin (PTX) solution; injecting the PTX solution with the same concentration into the abdominal cavity of the mouse after 48 hours; after 14 days, repeating the first operation to carry out secondary boosted immunization on the mouse; injecting the PTX solution into the abdominal cavity again after 16 days; and after 32-35 days, biological detection is carried out to determine that modeling succeeds. According to the construction method, the period is greatly shortened, and the experiment efficiency is improved; according to the method, through an optimized immune scheme, the model success rate is high, and the phenotype is stable; the model is an active immune model and can simulate a complete disease process from autoantibody generation and immune cell infiltration to central nervous system injury.

Described herein are single-domain antibodies that might serve as alternatives to conventional monoclonal antibodies for either the detection or treatment of Venezuelan equine encephalitis virus (VEEV).

The invention discloses a rabbit encephalitis microsporidia nested PCR specific primer as well as a detection method and application thereof, and relates to the technical field of rabbit encephalitis microsporidia detection. The invention relates to a nested PCR (Polymerase Chain Reaction) specific primer for rabbit encephalitis microsporidia. A gene sequence of an outer forward outer primer is shown as SEQ ID NO.2; the gene sequence of the outer reverse outer primer is as shown in SEQ ID NO.3; the gene sequence of the inner side forward inner primer is as shown in SEQ ID NO. 4; and the gene sequence of the inner side forward outer and inner primers is as shown in SEQ ID NO. 5. The nested PCR primer designed by the invention is high in specificity, can only identify E.cloniculi, has no cross reaction with related species, has sensitivity improved by 100 times compared with that of conventional PCR, can detect more low-concentration positive samples, and reduces the omission ratio; the matched kit fills the market blank, and provides efficient and accurate technical support for clinic and prevention and control.

The application provides application of Conessine in preparation of a medicine for resisting influenza A virus infection, and belongs to the technical field of biological medicine. 50＝ 0.45 muM, the value is low, and the inhibition efficiency is high. 50 The application also detects the toxicity of Conessine to cells, and finds that the toxicity of Conessine to cells is also low, and the CC 50 The safety index (SI) is much higher than the safety range, and the safety and effectiveness of Conessine as an IAV influenza A virus inhibitor are more guaranteed. Conessine can be used for treating respiratory system infection, pneumonia, encephalitis and other diseases caused by influenza A virus, and provides a new effective treatment medicine for global influenza epidemic.

Provided are a fusion antigen of porcine Getah virus (GETV), a kit, a preparation method therefor and an application thereof. The fusion antigen of the GETV is primarily prepared by recombining a Gaussia luciferase (GLuc) gene with a codon- optimized GETV E2 antigen gene to construct an expression vector, and transfecting the expression vector containing GLuc-E2 into mammalian cell lines, resulting in the secretion of GLuc-E2 proteins into a cell supernatant for expression. Without the need for protein purification step, the cell supernatant may be directly collected for disease detection. The present disclosure demonstrates strong specificity and shows no cross- reactivity with African swine fever virus (ASFV), porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus type 2 (PCV2), pseudorabies virus (PRV), or Japanese encephalitis virus (JEV).

Disclosed are compositions, vectors, and methods for treating and preventing rabies lyssavirus infection in a subject in need thereof, including rabies lyssavirus encephalitis. The disclosed compositions relate to anti-rabies immunoglobulins and vectors for expressing anti-rabies immunoglobulins such as adeno-associated virus (AAV) vectors that express anti-rabies immunoglobulins in a subject in need thereof. In some embodiments, the disclosed methods relate to treating and / or preventing an infection by rabies lyssavirus in a subject in need thereof, the methods comprising administering to the subject a dose of an adeno-associated virus (AAV) vector that expresses an immunoglobulin that binds and neutralizes rabies lyssavirus in the subject.

The present disclosure provides an application of Conessine in preparing an anti-influenza A virus (IAV) infection drug, falling within the technical field of biomedicine. In the present disclosure, the small molecule Conessine has a strong inhibitory effect against IAV, IC50=0.45 μM, with a low numerical value and high inhibitory efficiency. In the present disclosure, the toxicity of Conessine to cells is detected, it is found that the toxicity of Conessine to cells is also low, CC50 is high, a selection index (SI) is much higher than a safe range, and the safety and effectiveness of Conessine as an IAV inhibitor are more guaranteed. Conessine can be used for treating respiratory infections, pneumonia, encephalitis and other diseases caused by IAV, providing a new effective treatment drug for global influenza epidemic.

The invention relates to application of Liushen pills in treating diseases caused by various virus infections. The inventor finds that the Liushen pill has a good inhibition effect on various viruses, especially Coxsackie virus A type 9, respiratory syncytial virus, adenovirus C type 5, vaccinia virus, fever with thrombocytopenia syndrome bunyavirus, porcine epidemic diarrhea virus, pangolin coronavirus, Zika virus and Japanese encephalitis virus. In view of the strong inhibition effect on various viruses such as poxvirus, enterovirus, respiratory syncytial virus, adenovirus, bunyavirus, coronavirus and flavivirus observed by the Liushen pill, the Liushen pill is likely to become a specific medicine for diseases caused by infection of various viruses.

Provided is an alphavirus nonstructural protein 3 (nsP3) that is modified by at least a mutation at an amino acid position corresponding to amino acid position 167 of wild-type Venezuelan equine encephalitis virus (VEEV) nsP3 of SEQ ID NO: 1.

Disclosed are a fusion antigen of porcine Getah virus (GETV), a kit, a preparation method therefor and an application thereof. The fusion antigen of the GETV is primarily prepared by recombining a Gaussia luciferase (GLuc) gene with a codon-optimized GETV E2 antigen gene to construct an expression vector, and transfecting the expression vector containing GLuc-E2 into mammalian cell lines, resulting in the secretion of GLuc-E2 proteins into a cell supernatant for expression. Without the need for protein purification step, the cell supernatant may be directly collected for disease detection. The present disclosure demonstrates strong specificity and shows no cross-reactivity with African swine fever virus (ASFV), porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus type 2 (PCV2), pseudorabies virus (PRV), or Japanese encephalitis virus (JEV).

The invention discloses five Cas13d endonucleases and an RNA (Ribonucleic Acid) editing system mediated by the five Cas13d endonucleases. The Cas13d endonucleases are respectively Gs13d-1, Gs13d-2, Gs13d-3, Gs13d-4 and Gs13d-5, the amino acid sequences of the Cas13d endonucleases are respectively shown as SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, and each endonucleases corresponds to a specific DR sequence. The invention also provides a protein-coding polynucleotide sequence optimized by an eukaryotic codon, which is used for efficiently expressing the Cas13d endonuclease, and in addition, the invention relates to high-efficiency crRNA (Complementary Ribonucleic Acid) targeting JEV (Japanese encephalitis virus). The Cas13d endonucleases and the crRNA can be used for preparing antiviral drugs, and the antiviral effect is achieved by regulating and controlling virus RNA. Experimental results show that the Cas13d endonuclease provided by the invention has high efficiency and specificity in the aspect of regulating and controlling RNA expression, and a new strategy and tool are provided for accurate editing of RNA.